Abstract-IL-22 is known to induce intestinal epithelial cells (IECs) to produce the chemokine CXCL8. However, IECs exist in a cytokine network during mucosal inflammation, such that IL-22 must act in concert with potent pro-inflammatory cytokines like TNF-α and IL-1. Our studies show that IL-22 alone increased CXCL8 secretion from HT-29 cells, but the levels were minimal compared to that of the cells treated with TNF-α or IL-1 only. More significantly, co-stimulation with IL-22 and TNF-α enhanced both CXCL8 secretion and mRNA levels well over that of TNF-α stimulation alone. A similar enhancing effect was seen with IL-22-and IL-1-stimulated CXCL8 secretion. The enhancing effect of IL-22 on TNF-α-induced CXCL8 secretion was then determined to require the p38 MAPK, but not STAT1/3, PI3K, Akt, c-Jun N-terminal kinase, ERK, or IκBα. These experiments indicate that more significant effect of IL-22 on IECs responses may not be in inducing CXCL8 by itself, but in enhancing TNF-α-and IL-1-induced CXCL8 secretion to augment the contribution of IECs to local inflammatory responses.
INTRODUCTION
The epithelial cells that line the intestinal tract are constantly bombarded by a variety of bacteria and potential pathogens. Intestinal epithelial cells (IECs) not only respond to various microbial stimuli in the environment but also respond to cytokines produced by T cells and other cell types [1, 2] . In response to microbial or cytokine stimuli, IECs produce a variety of cytokines, including important chemokines like CXCL8 [3] . Due to their abundance, IECs are able to amplify inflammatory signals and recruit immune cells to the site of injury.
Inflammatory bowel disease (IBD) is characterized by a dramatic inflammation of the intestinal tissue with neutrophil accumulation on the intestinal crypts [2, 4] . Several studies have shown an increase in tissue levels of TNF-α in IBD [5, 6] such that current treatments for IBD have targeted TNF through monoclonal antibodies [1] . IECs respond to TNF-α by releasing several important cytokines and chemokines, suggesting that IECs play an important role in mucosal inflammation, such as in IBD [2, 4] .
IL-22 is a recently identified member of the IL-10-related cytokine family and is produced by activated Th17, Th1, Th22, and other cell types [7, 8] . Interestingly, a major target for IL-22 appears to be epithelial cells and keratinocytes, which express the IL-22 receptor [7] . Important to this study, the expression of the IL-22 receptor by both the Caco-2 and HT-29 cell lines has been confirmed [9] , making these cell lines excellent models to study the effect of IL-22 on IECs. IL-22 is highly expressed in many different chronic inflammatory diseases, including IBD [8] [9] [10] [11] . Furthermore, a risk locus for the ulcerative colitis form of IBD has been localized near the IL-22 gene on chromosome 12q15 [11] . This suggests an important role for IL-22 in the pathology of IBD. IL-22 stimulation of IECs has been shown to induce CXCL8 production [9] suggesting a pro-inflammatory function for this cytokine. Other studies support IL-22 as a pro-inflammatory cytokine [8, 10] or as protective cytokine with anti-inflammatory effects [8, 12] .
In IECs, IL-22 strongly signals through the JAK/ STAT pathways, activating mainly STAT3 and STAT1 [9] . However, IL-22 can activate MAPK signaling pathways, activating Akt/PKB, c-Jun N-terminal kinase (JNK), and ERK1/2 pathways in IECs [9] and also p38 MAPK in a variety of other cell types [8, 13, 14] .
During an inflammatory response, cytokines are not isolated from one another, but rather they work in concert within a signaling network. Although the role of IL-22 in inducing pro-inflammatory chemokine responses alone has been explored [9, 10] , the effect of IL-22 along with the potent pro-inflammatory cytokines TNF-α and IL-1 has not yet been explored for responses by IECs. As TNF-α, IL-1, and IL-22 can all induce the production of CXCL8, we hypothesized that IL-22, specifically in the presence of TNF-α or IL-1, may greatly modulate the production of CXCL8 production by IECs. Therefore, using the HT-29 and Caco-2 colonic carcinoma cell lines as models for IECs, we explored the effect of IL-22 along with TNF-α or IL-1 on the production of CXCL8. Moreover, we investigated the intracellular signaling pathways activated by IL-22 and TNF-α together to determine specifically how the effect occurred. The exploration of any IL-22 and TNF-α synergy could be very important to our understanding of the role of IL-22 within IBD-relevant signaling pathways and immune responses in the context of IECs, particularly given the known importance of TNF-α in chronic inflammatory diseases such as IBD.
MATERIALS AND METHODS

Antibodies
Recombinant human TNF-α and human IL-1β were obtained from R&D Systems (Minneapolis, MN) and recombinant human Interleukin-22 (IL-22) from Cell Signaling Technologies (Danvers, MA). Mouse monoclonal antibodies against human total IκBα and STAT3, rabbit monoclonal antibodies against human-phosphorylated IκBα and Tyr705-phosphorylated STAT3, rabbit antibodies to β-actin, and HRP-conjugated anti-rabbit and HRPconjugated anti-mouse detection antibodies were obtained from Cell Signaling Technologies.
Cell Culture for Cytokine Secretion
The human adenocarcinoma cell lines, HT-29 (ATCC HTB-38) and Caco-2 (ATCC HTB-37; American Type Culture Collection, Manassas, VA), were maintained in Dulbecco's modified Eagle medium (DMEM) (Thermo Scientific Hyclone Laboratories, Logan, UT) with 10% fetal bovine serum (FBS; Hyclone), 3.7 g/l sodium bicarbonate, 2 mM L-glutamine (Hyclone), non-essential amino acids (Cellgro, Manassas, VA), penicillin (25 IU), and streptomycin (25 μg/ml). The cells were cultured at 37°C in a 90% air-10% CO 2 humid environment. For chemokine secretion experiments, the cells were cultured at 2 × 10 5 cells/well (Caco-2) or 4 × 10 5 cells/well (HT-29) in 24-well culture plates for 24 h. The medium was then changed to serum-free DMEM containing insulin, transferrin, and selenium (ITS-DMEM; BD Biosciences, Bedford, MA), and the cells were treated with recombinant human TNF-α or IL-1β and/or recombinant human IL-22 as indicated. In some experiments, the cells were pretreated with specific inhibitors before cytokine stimulation. These included the PI3K inhibitor, Wortmannin (Sigma Aldrich) at 10 nM for 30 min; the Akt inhibitor V, Triciribine (Calbiochem/EMD Chemicals, Gibbstown, NJ) at 10 μM for 1 h; the STAT3 inhibitor VI S31-201 (EMD Millipore) at 100 μM; the JAK2/STAT3 inhibitor, WP1066 (Calbiochem), at 5 μM for 1 h; the STAT1 inhibitor, Fludarabine (Selleckchem, Houston, TX) at 25 μM; the Tyk2 inhibitor Bayer-18 (Symansis, New Zealand) at 40 nM or 60 nM; the JNK Inhibitor SP600125 (EMD Millipore, Billerica, MA) at 25 μM for 1 h; the ERK1/2 inhibitor PD98059 (Calbiochem) at 25 μM; or the p38 MAPK inhibitor SB203580 (Promega, Madison, WI) at 1 μM. After incubating the cultures for 24 h, the culture supernatants were collected and stored at −80°C and adherent cells were trypsin-EDTA treated and counted using a hemocytometer.
Secreted human CXCL8 was quantified by using the specific DuoSet ELISA kit (R&D Systems). The absorbances of the samples were measured using a Bio-Tek ELx808 microplate reader (Bio-Tek Instruments Inc., Winooski, VT), and the resulting chemokine concentration values were normalized to 10 5 cells.
RNA Isolation and Reverse-Transcription Real-Time PCR Analysis
HT-29 and Caco-2 cells were cultured in 10% FCS-DMEM at 1 × 10 6 cells/well in six-well tissue culture plates for 24 h. The medium was then changed to serum-free ITS-DMEM and the cells were treated with TNF-α (20 ng/ml) with or without IL-22 (100 ng/ml) for 6 h. The cells were lysed and RNA isolated using the Qiagen RNeasy mini RNA extraction kit (Qiagen Inc., Valencia, CA). The concentration of RNA was then measured using a Nanodrop Spectrophotometer ND-1000 (Thermo Scientific), and the samples were stored at −80°C.
An RNA sample of 1 μg was used to generate complementary DNA (cDNA) using the High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA) at 25°C for 10 min, 37°C for 120 min, and then the enzyme was heat inactivated at 85°C for 5 min. Samples were stored at −20°C. For the real-time PCR reaction, 4.5 μl of a 1:10 dilution of the cDNA reaction product was used in a total volume of 45 μl for analysis using primers for human CXCL8 and GAPDH (Qiagen). cDNA levels were quantified using the iQ SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA) and the Mini Opticon/MJ Mini personal thermal cycler (Bio-Rad). The amplification conditions were 3 min at 95°C followed by a two-step cycle of 95°C for 15 s and 60°C for 60 s for a total of 40 cycles. CXCL8 transcripts were then normalized to GAPDH transcripts for all corresponding conditions, and fold changes in CXCL8 were calculated using the threshold cycle (C t ) values. Data was analyzed using the Bio-Rad CFX Manager Software.
Western Blot Analysis
Cells were cultured at 1 × 10 6 cells/well in six-well tissue culture plates for 24 h. The medium was then changed to serum-free ITS-DMEM, and the cells were treated with TNF-α (20 ng/ml) with or without IL-22 (100 ng/ml) for the times indicated. The adherent cells were washed once with ice cold PBS before the addition of a 1× RIPA buffer solution (Cell Signaling Technology, Danvers, MA) containing 100 μM phenylmethylsulfonylfluoride and 100 μM 4-nitrophenyl phosphate (Sigma-Aldrich). The cells were kept on ice for 5 min followed by scraping with a cell scraper. The whole cell extracts were collected and incubated on ice for 15 min before centrifuging at 13,000×g in a cold centrifuge for 15 min. The supernatants were collected and stored at −80°C.
The extracts were diluted to equal amounts of protein in Laemmli buffer and were separated on 10% or 12% SDS-polyacrylamide resolving gels with 4% polyacrylamide stacking gels and Western blotted as previously published [15] . The membranes were blocked in 5% nonfat dry milk in Tris-buffered saline (TBS) with 0.1% (v/v) Tween-20 (TBS-T) or 5% BSA in TBS-T, as appropriate, for 1 h at room temperature before incubating with the appropriate primary antibody overnight at 4°C with mixing. The blots were then washed with TBS-T and incubated with either horseradish peroxidase-conjugated antimouse or anti-rabbit secondary antibodies (Cell Signaling Technology). After 1 h, the blots were washed with TBS-T and the bands were visualized using the SuperSignal West Pico Chemiluminescent Substrate Kit (Thermo Scientific, Rockford, IL) followed by exposure to X-ray film. For multiple reprobes of the same membrane, the blots were washed with TBS-T followed by incubation with a stripping buffer [15] at 50°C for 12 min. The membranes were again washed with TBS-T and blocked in 5% milk TBS-T or 5% BSA prior to probing with primary antibodies. Blots were scanned and band densities were quantified using the Quantity One software (Bio-Rad).
Statistical Analysis
For comparison of three or more separate experiments and analysis of significant difference, ANOVA and Fisher's protected least significant difference test with a level of significance set at p < 0.05 were performed using the Statview program (SAS Institute Inc., Cary, NC). Shown in all figures are the means ± the standard error of the mean (SEM) for three or more experiments unless otherwise indicated.
RESULTS
IL-22 Enhances TNF-α-or IL-1-Induced CXCL8 Secretion by Intestinal Epithelial Cell Lines
Studies have shown that TNF-α stimulation of IECs increases the production of various cytokines, including the chemokine CXCL8 [3, 16] . IL-22 has also been shown to stimulate the production of CXCL8, TNF-α, and antimicrobial proteins by IECs [9] . Since both IL-22 and TNF-α play a role in inflammation and are upregulated in IBD [1, 8] , we investigated whether IL-22 could potentiate the TNF-α-induced secretion of CXCL8 by IECs.
Studies in our laboratory found that treatment of Caco-2 [17] or HT-29 [unpublished results] human colonic epithelial cells with TNF-α at 20 ng/ml was sufficient to induce cytokine production by IECs. Therefore, using these cell lines as models for IECs, the cells were treated with TNF-α at 20 ng/ml with or without IL-22 at 2, 20 or 100 ng/ml. When the values for CXCL8 secretion by cells treated with IL-22 alone were compared by ANOVA to unstimulated controls only without the TNF-α stimulated values (Fig. 1a) , IL-22 at both 20 and 100 ng/ml significantly increased CXCL8 production by HT-29 cells over the untreated controls by up to a 5.6-fold (p < 0.05 and p < 0.01, respectively). This is consistent with previous studies [9] . Next, as expected, HT-29 cells cultured with TNF-α alone (20 ng/ml) resulted in a significant 82-fold increase in CXCL8 production by over that of the untreated control (p < 0.0001). Treatment of the HT-29 cells with both TNF-α and IL-22 at all concentrations also resulted in significant increases in CXCL8 production compared to cells treated with TNF-α alone with a maximum of a 1.9-fold increase with 100 ng/ml of IL-22 (Fig. 1a) . Treatment of the cells with both TNF-α and 100 ng/ml IL-22 resulted in a 153-fold increase in CXCL8 secretion compared to the unstimulated controls. This suggests that IL-22 can significantly enhance TNF-induced CXCL8 secretion by IECs. Of note, these culture supernatants were also tested for levels of CCL20, and although TNF-α did stimulate CCL20 secretion by the HT-29 cells, IL-22 had no additional effect on CCL20 secretion (data not shown).
The enhancing effect of IL-22 on TNF-α stimulated CXCL8 secretion was next verified in a second experiment using the Caco-2 cell line. Although IL-22 stimulation by itself did result in a 5-fold increase in CXCL8 levels, the levels were not significantly different from the untreated controls even with 100 ng/ml IL-22. As shown in Fig. 1b , when Caco-2 cells were cultured with TNF-α alone, CXCL8 secretion was significantly increased by 60-fold compared to that of the untreated control (p < 0.01). Stimulation of the cells with both TNF-α and IL-22 also significantly enhanced CXCL8 secretion by 102-fold compared to the controls. Yet more importantly, TNF-α and IL-22 stimulations resulted in a 1.7-fold increase in CXCL8 secretion as compared to cells treated with TNF-α only, but only with the highest concentration of IL-22 of 100 ng/ml. This confirms that IL-22 can significantly enhance TNF-α induced CXCL8 secretion by IECs.
Since IL-1 can signal through several intracellular pathways similar to TNF-α, the effect of IL-22 co-stimulation with IL-1β on HT-29 cells was determined. The results in Fig. 1c show that IL-22 stimulation at 100 ng/ ml could significantly enhance IL-1β-stimulated CXCL8 secretion by 1.9-fold compared to cells treated with IL-1β only, indicating that IL-22 could also enhance IL-1-stimulated CXCL8 secretion by IECs.
Effect of TNF-ɑ and IL-22 on CXCL8 mRNA Expression in IECs
Next, the effect of IL-22 on TNF-α-stimulated messenger RNA (mRNA) levels was determined using reverse transcription-real-time PCR analysis (Fig. 2) . Treatment of the cells with IL-22 alone had no significant effect on CXCL8 mRNA levels in both the HT-29 or Caco-2 cells (p > 0.7). However, stimulation of the cells with both IL-22 and TNF-α resulted in a significant 1.7-and 1.5-fold increase in CXCL8 mRNA levels in HT-29 and Caco-2 cells, respectively, as compared to cells treated with TNF-α alone at 6 h. This suggests that the enhancing effect of IL-22 may be on the intracellular signaling events occurring prior to transcription.
IL-22 and TNF-α Effects on Intracellular Signaling Pathways
The binding of TNF-α to TNFR1 leads to the intracellular recruitment of MAPK pathway signal transducers, inducing the c-Jun N-terminal kinase (JNK), p38 MAPK, and ERK1/2 kinases, as well as signaling transducers in the IKK/IκBα/NF-κB signaling pathway. Signaling through these pathways can then activate several transcription factors such as AP-1, NF-κB, and others [18, 19] . The IL-22 receptor has been shown to signal through Akt/PKB, JNK, ERK1/2, and p38 MAPK pathways [8, 9, 13, 14] , which have been shown to control CXCL8 responses [20] . However, a major signaling pathway associated with this IL-22 is the JAK/STAT pathway to activation of STAT3 and STAT1 in IECs [9] .
To determine the signaling pathways involved, a variety of well-known chemical inhibitors specific for the various signaling pathways were used prior to treatment with IL-22 and/or TNF-α. As shown in Table 1 , the enhancing effect of IL-22 on TNF-α-stimulated HT-29 CXCL8 secretion was not significantly affected by inhibiting signaling through JAK2/STAT3, STAT1, Tyk2, phosphatidylinositol-4, 5-bisphosphate 3-kinase (PI3K), Akt (PKB), JNK, or ERK1/2. This suggests that these kinase signaling pathways were not involved in the enhancing effect of IL-22.
Since IL-22 signaling through STAT3 has been shown to be a major signaling pathway for this cytokine, we sought to confirm that this signaling pathway was not involved. Figure 3a , b shows that IL-22, but not TNF-α, induced a strong activation of STAT-3 phosphorylation within 5 min that remained elevated for at least 30 min. However, treatment of the cells with the JAK2 inhibitor WP1066 had no effect on the enhancing effect of IL-22 on TNF-α-induced CXCL8 secretion (Table 1) . To further confirm this result, HT-29 cells were treated with the STAT3 specific inhibitor, STAT3 inhibitor VI. Treatment of the cells with this specific inhibitor had no effect on the enhancement of TNF-induced CXCL8 secretion induced by IL-22 (Fig. 3c) . These experiments strongly confirm that the enhancing effect of IL-22 was not due to STAT3 signaling. Fig. 2 . IL-22 enhances TNF-α induced increases in CXCL8 mRNA levels. HT-29 (a) and Caco-2 (b) cells were cultured for 24 h before adding TNF-α (20 ng/ml) and/or IL-22 (100 ng/ml). The cells were then incubated for 6 h, and total RNA was isolated for reverse transcription and realtime PCR analysis with primers for CXCL8 and GAPDH as the control. Shown are the means ± SEM (n = 3). *Significant difference from unstimulated control cells (p < 0.0001). of the inhibitors, with or without IL-22 and/or TNF-α as in Fig. 3 
Effect of IL-22 on IκBα Phosphorylation and Degradation
One of the major mechanisms for activation of CXCL8 gene transcription is through the activation of NF-κB [20] . Activation of NF-κB requires the phosphorylation and degradation of its inhibitor, IκBα [19] . Therefore, we next determined the effect of IL-22 on TNF-α-induced IκBα phosphorylation and degradation. As shown in Fig. 4a, b , IL-22 alone had no effect on IκBα phosphorylation. However, treatment of the cells with IL-22 and TNF-α resulted in a significant suppression of IκBα phosphorylation at 30 min, yet this suppression was still significantly elevated compared to the untreated controls. Furthermore, treatment of the HT-29 cells with TNF-α or IL-22 and TNF-α resulted in a significant degradation of total IκBα levels at 30 min (Fig. 4a, c) . These results could indicate that IL-22 may delay IκBα phosphorylation, Fig. 3 . The role of STAT3 in the enhancement of TNF-α-induced CXCL8 responses by IL-22. a HT-29 cells were cultured for 24 h before adding TNF-α (20 ng/ml) and/or IL-22 (100 ng/ml) in ITS-DMEM. At the times indicated, whole cell lysates were collected, separated by SDS-PAGE and were Western blotted for Tyr705 phosphorylated and total STAT3. Shown is a representative blot from three separate experiments. b Graph shows the means ± SEM of the band densities of phosphorylated Tyr705 STAT3 normalized to total STAT3 for three separate experiments. *Significant difference from unstimulated control cells (p < 0.001). c HT-29 cells were prepared as in Fig. 1 except that the cells were pre-treated with or without the STAT3 inhibitor-VI S31-201 (100 μM) for 1 h before treatment with TNF-α and IL-22. Shown are the means ± SEM (n = 3). *Significant difference from the unstimulated cells (p < 0.0001). but ultimately may have little overall effect on this signaling pathway as secreted CXCL8 levels were not suppressed.
Effect of IL-22 and TNF-α on p38 MAPK Signaling
Both IL-22 and TNF-α are also known to signal through the p38 MAPK pathway [8, 13, 19] . Signaling through p38 MAPK can enhance CXCL8 responses by activating mechanisms that enhance the stability of mRNA and indirectly through affecting histone phosphorylation [20, 21] . As expected since TNF-α signals through p38 MAPK, pre-treatment of the HT-29 cells with the p38 MAPK inhibitor SB203580 resulted in a suppression of TNF-α-induced CXCL8 secretion (Fig. 5) . More importantly, pre-treatment with the p38 MAPK inhibitor resulted in a complete abrogation of the enhancing effect of IL-22 on TNF-α-stimulated CXCL8 secretion. Therefore, the enhancing effect of IL-22 must involve signaling through the p38 MAPK.
DISCUSSION
During an inflammatory response, cells are exposed to a network of cytokines. Recent reports have shown that IL-22 plays an important role in IBD [11] , and as such belongs in this network of cytokines present during mucosal inflammatory responses. Yet, the wellcharacterized pro-inflammatory cytokines, TNF-α and IL-1, are major cytokines known to be important in chronic inflammatory diseases and TNF-α is a major driver for the production of pro-inflammatory cytokines by IECs in mucosal inflammatory diseases [4] . Therefore, any discussion on the role of IL-22 in mucosal inflammation must consider its effect in the context of the potent pro-inflammatory cytokines like TNF-α and IL-1.
IL-22 is expressed in IBD tissues [9] and IECs express IL-22 receptors, making them a major target for IL-22 [7] . Indeed, IL-22 has been shown to induce IEC proliferation, survival signals, and wound healing along with inducing IECs to produce anti-microbial peptides [11] . IL-22 may also play a role in inflammation by inducing IECs to produce CXCL8 [9] . Since IL-22, TNF-α, and IL-1 can all induce IECs to produce CXCL8, we examined the co-stimulatory effect of IL-22 with these proinflammatory cytokines on CXCL8 responses in IEC cell lines.
Although IL-22 alone did induce low levels of CXCL8 secretion from the HT-29 cell line, this level was relatively insignificant compared to the level of CXCL8 secreted after TNF-α or IL-1β stimulation. This suggests that by itself, IL-22 had little effect on CXCL8 responses by IECs. However, co-stimulation of IECs with both TNF-α and IL-22 or IL-1β and IL-22 resulted in an enhanced level of CXCL8 secretion. This costimulatory enhancing effect was also seen with increased levels of CXCL8 mRNA levels. This suggests that the true effect of IL-22 on chemokines may be to enhance TNF-or IL-1-stimulated CXCL8 responses by IECs in mucosal tissues.
Experiments were next performed to determine the mechanism through which IL-22 enhanced proinflammatory cytokine responses, focusing on TNF-α stimulation as both TNF-α and IL-1 signal through similar downstream pathways. IL-22 has been shown to induce intracellular signaling through the JAK/STAT signaling pathway to activate STAT1 and STAT3 [9] , as well as the Akt/PKB, JNK, ERK1/2, and p38 MAPK pathways [8, 9, 13, 14] . Although all of the latter pathways have been linked to regulating CXCL8 responses [20] , using well-known inhibitors of these signaling kinases revealed that only the p38 MAPK appeared to be involved in the enhancing effect of IL-22 on TNF-α-stimulated CXCL8 secretion. Indeed, even though STAT3 is a major signaling pathway for the IL-22 receptor, the STAT3 that was not involved in the effect was confirmed with two different inhibitors as well as inhibitors of JAK2 and Tyk2. Furthermore, even though IL-22 has been shown to enhance NF-κB responses through an effect on IκBα in colonic subepithelial myofibroblasts [10] , IL-22 had no enhancing effect on IκBα phosphorylation or degradation with TNF-α stimulation of the HT-29 cells. Indeed, a suppressive effect of IL-22 on IκBα phosphorylation after 30 min was actually found. Yet since TNF-α-induced CXCL8 secretion levels were enhanced with IL-22 co-stimulation, this suppressive effect of IL-22 on IκBα phosphorylation was apparently not important and may have been reflective of a delay in IκBα phosphorylation. Still, the significance of this suppressive effect of IL-22 on IκBα phosphorylation remains unknown.
Many reports have shown that p38 MAPK can greatly e nhance CXCL8 respon se s by po sttranscriptionally prolonging the half-life of CXCL8 mRNA [22] . This effect occurs through phosphorylation of the downstream MK2/3 kinases by p38 MAPK [21] . MK2/3 then phosphorylates the tristetraprolin (TTP) AU-rich element-binding protein, leading to an inhibition of the TTP-dependent degradation of CXCL8 mRNA [23] . The p38 MAPK can also phosphorylate histone H3, resulting in chromatin modulation to enhance the availability of NF-κB binding sites on cytokine gene promoters [21] . This provides two powerful mechanisms by which IL-22 could enhance TNF-α-mediated CXCL8 responses in IECs.
Studies suggest that IL-22 has several pro-and anti-inflammatory effects. An enhancing effect of IL-22 on TNF-α or IL-1-stimulated CXCL8 responses could lead to increased neutrophil migration into inflamed mucosal tissues in diseases like IBD, thus exacerbating the detrimental inflammation. However, a role for CXCL8 in wound healing responses exists in that CXCL8 can enhance angiogenesis in several tissues and cancer [24] . Thus, a CXCL8-enhanced angiogenic effect would be consistent with the wound healing aspects of IL-22. Therefore, our studies could support both a pro-inflammatory and wound healing effect of IL-22 in a cytokine network with TNF-α and IL-1, suggesting caution when targeting this cytokine for future anti-inflammatory therapies.
